IL286099A - Methods of treating the disease using levoketoconazole - Google Patents
Methods of treating the disease using levoketoconazoleInfo
- Publication number
- IL286099A IL286099A IL286099A IL28609921A IL286099A IL 286099 A IL286099 A IL 286099A IL 286099 A IL286099 A IL 286099A IL 28609921 A IL28609921 A IL 28609921A IL 286099 A IL286099 A IL 286099A
- Authority
- IL
- Israel
- Prior art keywords
- levoketoconazole
- methods
- treating disease
- disease
- treating
- Prior art date
Links
- XMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229950001948 levoketoconazole Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813399P | 2019-03-04 | 2019-03-04 | |
| PCT/US2020/020644 WO2020180784A1 (en) | 2019-03-04 | 2020-03-02 | Methods of treating disease with levoketoconazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286099A true IL286099A (en) | 2021-10-31 |
Family
ID=72338256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286099A IL286099A (en) | 2019-03-04 | 2021-09-02 | Methods of treating the disease using levoketoconazole |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11020393B2 (https=) |
| EP (1) | EP3934649A4 (https=) |
| JP (2) | JP7574204B2 (https=) |
| KR (2) | KR102950333B1 (https=) |
| CN (1) | CN113710250A (https=) |
| AU (2) | AU2020232246B2 (https=) |
| BR (1) | BR112021017561A2 (https=) |
| CA (1) | CA3132319A1 (https=) |
| IL (1) | IL286099A (https=) |
| WO (1) | WO2020180784A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7574204B2 (ja) * | 2019-03-04 | 2024-10-28 | ストロングブリッジ ダブリン リミテッド | レボケトコナゾールによる疾患の処置方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006204334B2 (en) * | 2005-01-10 | 2012-02-23 | Cortendo Ab (Publ) | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
| AU2007303219A1 (en) * | 2006-10-02 | 2008-04-10 | Cortendo Ab (Publ) | Ketoconazole enantiomer in humans |
| TWI690521B (zh) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| US11261157B2 (en) * | 2016-12-08 | 2022-03-01 | Novatarg, Inc. | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy |
| US10512667B2 (en) * | 2017-06-27 | 2019-12-24 | The Regents Of The University Of Michigan | Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production |
| JP7574204B2 (ja) * | 2019-03-04 | 2024-10-28 | ストロングブリッジ ダブリン リミテッド | レボケトコナゾールによる疾患の処置方法 |
-
2020
- 2020-03-02 JP JP2021552515A patent/JP7574204B2/ja active Active
- 2020-03-02 KR KR1020217031645A patent/KR102950333B1/ko active Active
- 2020-03-02 KR KR1020267010641A patent/KR20260049881A/ko active Pending
- 2020-03-02 WO PCT/US2020/020644 patent/WO2020180784A1/en not_active Ceased
- 2020-03-02 CN CN202080029583.4A patent/CN113710250A/zh active Pending
- 2020-03-02 BR BR112021017561A patent/BR112021017561A2/pt unknown
- 2020-03-02 CA CA3132319A patent/CA3132319A1/en active Pending
- 2020-03-02 AU AU2020232246A patent/AU2020232246B2/en active Active
- 2020-03-02 EP EP20766266.9A patent/EP3934649A4/en active Pending
- 2020-09-02 US US17/010,387 patent/US11020393B2/en active Active
-
2021
- 2021-05-13 US US17/319,781 patent/US11278547B2/en active Active
- 2021-09-02 IL IL286099A patent/IL286099A/en unknown
-
2022
- 2022-03-21 US US17/655,632 patent/US11903940B2/en active Active
-
2024
- 2024-01-16 US US18/414,250 patent/US12377096B2/en active Active
- 2024-10-16 JP JP2024180821A patent/JP7801408B2/ja active Active
-
2025
- 2025-06-12 AU AU2025204382A patent/AU2025204382A1/en active Pending
- 2025-07-02 US US19/257,990 patent/US20250387389A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025204382A1 (en) | 2025-07-03 |
| JP7574204B2 (ja) | 2024-10-28 |
| AU2020232246B2 (en) | 2025-03-20 |
| KR20260049881A (ko) | 2026-04-14 |
| US20200397781A1 (en) | 2020-12-24 |
| KR20210135278A (ko) | 2021-11-12 |
| US20240148724A1 (en) | 2024-05-09 |
| US11278547B2 (en) | 2022-03-22 |
| JP7801408B2 (ja) | 2026-01-16 |
| WO2020180784A1 (en) | 2020-09-10 |
| KR102950333B1 (ko) | 2026-04-08 |
| BR112021017561A2 (pt) | 2021-11-09 |
| US11020393B2 (en) | 2021-06-01 |
| JP2025026838A (ja) | 2025-02-26 |
| EP3934649A1 (en) | 2022-01-12 |
| US20210267970A1 (en) | 2021-09-02 |
| EP3934649A4 (en) | 2022-11-23 |
| US11903940B2 (en) | 2024-02-20 |
| US20220387425A1 (en) | 2022-12-08 |
| US20250387389A1 (en) | 2025-12-25 |
| CN113710250A (zh) | 2021-11-26 |
| JP2022522873A (ja) | 2022-04-20 |
| US12377096B2 (en) | 2025-08-05 |
| CA3132319A1 (en) | 2020-09-10 |
| AU2020232246A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277333A (en) | Methods for treating eye diseases | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL274541A (en) | A method for treating diseases of the digestive tract using Tradifitant | |
| IL283508A (en) | Disease treatment methods with magl inhibitors | |
| IL277981A (en) | Cancer treatment methods | |
| IL277500A (en) | A method for treating fibrotic disease | |
| PT3600415T (pt) | Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL284791A (en) | Disease treatment methods with MAGL inhibitors | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| IL281600B2 (en) | Cancer treatment methods | |
| IL253847A0 (en) | Methods of treating diseases | |
| IL290983A (en) | Treatment methods | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| SG11202102878TA (en) | Treatment methods | |
| SG11202102827YA (en) | Treatment methods | |
| GB201907305D0 (en) | Treatment of conditions | |
| GB202015959D0 (en) | Treatment of diseases involving NAD | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| GB201918853D0 (en) | Methods of treatment | |
| IL286099A (en) | Methods of treating the disease using levoketoconazole | |
| SG11202105877YA (en) | Method of treatment | |
| GB201820098D0 (en) | Methods of cancer treatment | |
| IL291626A (en) | Celiac treatment | |
| IL268111A (en) | Methods of treating pain |